Andrew D. Krahn, MD, FHRS discusses this article with guests Jason D. Roberts, MD and Julia Cadrin-Tourigny, MD, PhD, CCDS. Clinical guidelines recommend regular screening for arrhythmogenic right ventricular cardiomyopathy (ARVC) to monitor at-risk relatives, resulting in a significant burden on clinical resources. Prioritizing relatives on their probability of developing definite ARVC may provide more efficient patient care.
https://www.hrsonline.org/education/TheLead
Host Disclosure(s):
A. Krahn: Honoraria/Speaking/Consulting Fee: Medtronic, Inc
Contributor Disclosure(s):
J. Roberts: Honoraria/Speaking/Consulting Fee: Ionis Pharmaceuticals
J. Cadrin-Tourigny: Honoraria/Speaking/Consulting Fee: BMS/Pfizer Alliance, Bayer Healthcare Pharmaceuticals, Tenaya Therapeutics